Related Experiment Video
Updated: May 7, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Assessment of targets of antibody drug conjugates in SCLC
Abhishek Ajay1, Han Wang2, Ali Rezvani3
1Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, and Case Western Reserve University, Cleveland, OH, USA.
Abstract:
Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance the effectiveness of ADC therapies in SCLC, we focused on target selection in this study by investigating the expression of ADC targets - SEZ6, DLL3, CD276, and TACSTD2 - in cell lines and patient samples. SEZ6 expression was significantly elevated in various SCLC transcriptional subtypes, particularly ASCL1, and exhibited gender-specific differences, being lower in women. DLL3 was primarily observed in the ASCL1 subtype, while CD276 showed high expression in non-neuroendocrine subtypes. TACSTD2 levels were generally low and attenuated in lymph nodes and brain metastases compared to primary tumors. Our findings underscore the importance of understanding target expression patterns to optimize ADC therapy and advance precision medicine in SCLC treatment.
Insights
Antibody-drug conjugate (ADC) therapy shows promise for small cell lung cancer (SCLC). This study investigated ADC targets (SEZ6, DLL3, CD276, TACSTD2) in SCLC, revealing subtype-specific expression crucial for optimizing treatment.
Area of Science:
- Oncology
- Translational Medicine
- Molecular Biology
Background:
- Antibody-drug conjugate (ADC) therapy has revolutionized cancer treatment, including for small cell lung cancer (SCLC).
- Current challenges in SCLC ADC therapy include systemic toxicity, treatment resistance, and the need for better patient selection biomarkers.
- Understanding the expression patterns of potential ADC targets is critical for improving therapeutic efficacy.
Purpose of the Study:
- To investigate the expression levels of key ADC targets: SEZ6, DLL3, CD276, and TACSTD2.
- To analyze target expression across different SCLC transcriptional subtypes and patient demographics.
- To identify potential biomarkers for guiding ADC therapy selection in SCLC.
Main Methods:
- Analysis of SEZ6, DLL3, CD276, and TACSTD2 expression in SCLC cell lines and patient samples.
- Correlation of target expression with SCLC transcriptional subtypes (e.g., ASCL1).
- Assessment of target expression in primary tumors versus metastatic sites (lymph nodes, brain).
Main Results:
- SEZ6 demonstrated significantly elevated expression in multiple SCLC subtypes, notably ASCL1, with lower levels observed in female patients.
- DLL3 expression was predominantly found in the ASCL1 subtype.
- CD276 showed high expression in non-neuroendocrine SCLC subtypes, while TACSTD2 levels were generally low and reduced in metastatic sites.
Conclusions:
- Target expression in SCLC is heterogeneous and subtype-specific, impacting ADC therapy potential.
- SEZ6 and DLL3 are promising targets, particularly in the ASCL1 subtype, with gender-specific considerations for SEZ6.
- Understanding these expression profiles is vital for advancing precision medicine and optimizing ADC strategies in SCLC.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
